{"entity":{"id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.","summary":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07455851 by Regeneron Pharmaceuticals, with 150 participants planned, started 2026-03-26 and due to reach its primary completion in 2033-09-30. Interventions recorded: Linvoseltamab, REGN17372+Linvoseltamab. Conditions listed: Relapsed Refractory Multiple Myeloma (RRMM). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07455851","url":"https://clinicaltrials.gov/study/NCT07455851"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["linvoseltamab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07455851","phase":"1/2","setting":"A FIH Phase 1/2 Study to Assess Safety, Tolerability, and Preliminary Anti-Tumor Activity of REGN17372, an Anti-GPRC5D x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Linvoseltamab, an Anti-BCMA x Anti-CD3 Bispecific Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","enrolled":150,"outcomes":[]},"route":"/trials/nct07455851/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}